What are the recommended initiation, dosing, monitoring, contraindications, and management steps for desidustat (Oxemia) in adult non‑dialysis chronic kidney disease patients with eGFR <60 mL/min/1.73 m² and hemoglobin <10 g/dL?

Desidustat (Oxemia) for Anemia in Non-Dialysis CKD

Desidustat is an oral HIF-prolyl hydroxylase inhibitor approved in India for treating anemia in adult non-dialysis CKD patients, initiated at 100 mg three times weekly when hemoglobin is <10 g/dL and eGFR <60 mL/min/1.73 m². 1, 2

Initiation Criteria

Start desidustat when ALL of the following are met:

• Adult patient with confirmed CKD (eGFR <60 mL/min/1.73 m²) 2
• Hemoglobin <10 g/dL 3, 2
• Not on dialysis 1, 2
• Iron stores optimized first: TSAT >20% and ferritin >100 ng/mL 3

Before initiating, rule out:

• Active malignancy (particularly when cure is anticipated) 3
• Recent stroke history 3
• Correctable causes of anemia (B12/folate deficiency, bleeding, hemolysis) 3

Dosing Protocol

Standard dosing regimen:

• Initial dose: 100 mg orally three times weekly (every alternate day) 4, 2
• Administration: Take in fasting conditions 4
• Dose titration: Can increase to 150 mg or 200 mg three times weekly based on hemoglobin response 4, 2
• Target hemoglobin: 10-12 g/dL 5

Dose adjustment strategy:

• If hemoglobin increases <1 g/dL after 6 weeks, increase to 150 mg three times weekly 4
• If still inadequate response, may increase to 200 mg three times weekly 4
• If hemoglobin exceeds 12 g/dL, temporarily hold and restart at lower dose when <11 g/dL 5

Monitoring Requirements

Hemoglobin monitoring:

• Baseline, then every 2 weeks for first 8 weeks 3, 2
• Once stable (Weeks 16-24), monthly monitoring 2
• Check more frequently if dose adjustments made 3

Iron parameters:

• Baseline ferritin and TSAT 3
• Recheck at Week 12 and Week 24 2
• Maintain TSAT >20% and ferritin >100 ng/mL throughout treatment 3

Additional monitoring:

• Blood pressure at each visit (risk of hypertension with erythropoiesis-stimulating agents) 3
• Serum potassium if on RAAS inhibitors 3
• Lipid profile at baseline and Week 24 (desidustat may reduce LDL) 2
• VEGF levels at baseline, Week 12, and Week 24 2

Absolute Contraindications

Do not use desidustat in:

• Active malignancy where cure is the goal 3
• Recent stroke (within past year) 3
• Uncontrolled hypertension (>140/90 mm Hg) 3
• Known hypersensitivity to HIF-PH inhibitors 1

Relative Contraindications (Use with Caution)

• History of malignancy (cancer-free >5 years may be acceptable) 3
• History of stroke (>1 year ago, assess risk-benefit) 3
• Severe iron deficiency (ferritin <100 ng/mL, TSAT <20%) - correct first 3
• Proliferative diabetic retinopathy (theoretical VEGF concern, though not significant in trials) 2

Management Algorithm

Step 1: Optimize iron stores BEFORE starting desidustat

• If TSAT <20% or ferritin <100 ng/mL, give intravenous iron first 3
• Reassess iron parameters after 4-8 weeks 3
• Oral iron is less effective in CKD; prefer IV iron 3

Step 2: Initiate desidustat at 100 mg three times weekly

• Administer on fasting stomach 4
• Continue iron supplementation (oral or IV as needed) 3, 2

Step 3: Assess response at Week 6

• Good response (Hb increase ≥1 g/dL): Continue same dose 4
• Inadequate response (Hb increase <1 g/dL): Increase to 150 mg three times weekly 4
• Excessive response (Hb >12 g/dL): Hold temporarily, restart at lower dose when Hb <11 g/dL 5

Step 4: Reassess at Week 12

• If still inadequate response on 150 mg, increase to 200 mg three times weekly 4
• Check iron parameters, replete if deficient 2
• Verify medication adherence 3

Step 5: Maintenance phase (Weeks 16-24 and beyond)

• Continue dose that maintains Hb 10-12 g/dL 2, 5
• Monthly hemoglobin monitoring 2
• Quarterly iron parameters 2

Common Pitfalls and How to Avoid Them

Pitfall 1: Starting desidustat without optimizing iron stores

• Always correct iron deficiency FIRST with IV iron 3
• Functional iron deficiency will limit erythropoietic response 3

Pitfall 2: Targeting hemoglobin >12 g/dL

• Higher hemoglobin targets (>13 g/dL) increase cardiovascular risk and mortality 3
• Target range is 10-12 g/dL, NOT higher 5

Pitfall 3: Ignoring blood pressure changes

• Hypertension is a known adverse effect of erythropoiesis stimulation 3
• Intensify antihypertensive therapy as needed; target BP <130/80 mm Hg in CKD 3

Pitfall 4: Not checking for ESA resistance

• If no response after 12 weeks at maximum dose (200 mg), investigate: 3
  • Ongoing blood loss or hemolysis
  • Severe hyperparathyroidism
  • Aluminum toxicity
  • Chronic inflammation/infection
  • Bone marrow disorders

Pitfall 5: Continuing desidustat during acute illness

• Temporarily hold during serious infections, hospitalizations, or surgery 3
• Risk of thrombotic events may increase during acute inflammatory states 3

Efficacy Data

Expected hemoglobin response:

• Mean Hb increase of 1.95 g/dL from baseline to Weeks 16-24 2
• 78% of patients achieve ≥1 g/dL increase (responder rate) 2
• Non-inferior to darbepoetin (ESA comparator) 2

Additional benefits:

• Significant reduction in hepcidin levels (improves iron utilization) 2
• Modest reduction in LDL cholesterol 2
• Oral administration (vs. subcutaneous ESAs) improves convenience 1, 2

Safety Profile

Common adverse events (comparable to ESAs):

• Hypertension (monitor and treat aggressively) 3, 2
• Headache 4
• Peripheral edema 4

Serious adverse events (rare, similar to ESA therapy):

• Thrombotic events (dialysis access thrombosis, stroke, MI) 3
• Seizures 3
• Pure red cell aplasia (extremely rare with oral agents) 3

No new safety signals identified in Phase 3 trials compared to ESAs 2, 5

Comparison to Traditional ESA Therapy

Advantages of desidustat over ESAs:

• Oral administration (no injections) 1, 2
• Improves iron utilization via hepcidin suppression 2
• May improve lipid profile 2
• Similar efficacy and safety to darbepoetin and epoetin 2, 5

When to prefer ESAs over desidustat:

• Dialysis-dependent patients (though desidustat also approved for this in India) 5
• Rapid correction needed (ESAs may act faster initially) 3
• Patient preference for less frequent dosing (some ESAs dosed every 2-4 weeks) 3

Integration with CKD Management

Continue evidence-based CKD therapies:

• SGLT2 inhibitors (if eGFR ≥20 mL/min/1.73 m² and type 2 diabetes) 3, 6
• ACE inhibitors or ARBs (if hypertension with albuminuria) 3
• Statins for cardiovascular protection 3
• Blood pressure target <130/80 mm Hg 3

Desidustat does not replace these foundational therapies 3